MRI-based tumour control probability in skull-base chordomas treated with carbon-ion therapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
08 2019
Historique:
received: 14 01 2019
revised: 30 03 2019
accepted: 18 04 2019
pubmed: 6 5 2019
medline: 9 4 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

To derive personalized tumour control probability (TCP) models, using diffusion-weighted (DW-) MRI for defining initial tumour cellular density in skull-base chordoma patients undergoing carbon-ion radiotherapy (CIRT). 67 patients affected by skull-base chordoma were enrolled for a standardized CIRT treatment (70.4 Gy (RBE) prescription dose). Local control information was clinically assessed. For 20 of them, apparent diffusion coefficient (ADC) maps were computed from DW-MRI and then converted into cellular density. Radiosensitivity parameters (α, β) were estimated from the available data through an optimization procedure, taking advantage of a relationship observed between local control and the dose received by at least the 98% of the gross tumour volume. These parameters were fed into two poissonian TCP models, based on the LQ model, being the first (TCP The inclusion of the cellular density derived from ADC into TCP Both TCP

Identifiants

pubmed: 31051372
pii: S0167-8140(19)30370-6
doi: 10.1016/j.radonc.2019.04.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-37

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Giulia Buizza (G)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy. Electronic address: giulia.buizza@polimi.it.

Silvia Molinelli (S)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Emma D'Ippolito (E)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Giulia Fontana (G)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Andrea Pella (A)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Francesca Valvo (F)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Lorenzo Preda (L)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Italy.

Roberto Orecchia (R)

National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Guido Baroni (G)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy; National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.

Chiara Paganelli (C)

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH